Tracy Beth Høeg, the newly appointed top drug regulator at the Food and Drug Administration, outlined her priorities in her first address to staff. She emphasized the need to closely examine the safety of antidepressants used by pregnant women and monoclonal antibodies used to protect infants from RSV.
During her speech on Thursday, Høeg expressed her concern about the lack of comprehensive safety monitoring for these products during pregnancy. She highlighted the importance of conducting thorough evaluations to ensure the well-being of expectant mothers and their babies.
“I’ve discovered that there is a gap in our safety monitoring efforts for these products during pregnancy, and I believe we can improve in this area,” Høeg stated. “There seems to be consensus on this issue among the CDER staff I have consulted with, and I am eager to address this.”
Høeg’s focus on evaluating the safety of antidepressants and RSV monoclonal antibodies reflects her commitment to safeguarding public health. By prioritizing these critical areas, she aims to enhance the FDA’s regulatory oversight and ensure that these medications are safe and effective for their intended use.
As Høeg embarks on her new role, she brings a wealth of experience and expertise to the FDA. Her dedication to promoting drug safety and her proactive approach to addressing emerging concerns make her a valuable asset to the agency.
In conclusion, Høeg’s emphasis on evaluating antidepressants and RSV monoclonal antibodies underscores the FDA’s commitment to protecting the health and well-being of patients. By prioritizing these important issues, she sets a strong foundation for her leadership and the agency’s regulatory efforts in the coming years.
